Adenocarcinoma as an Independent Risk Factor for Disease Recurrence in Patients with Stage IB Cervical Carcinoma
Between 1960 and 1989 1538 patients were treated with initial radiation therapy for FIGO Stage IB squamous cell carcinoma (SCC) of the cervix and 229 patients were treated for Stage IB adenocarcinoma (AC). The overall 5-year survival rates for patients with SCC and AC were 81 and 72%, respectively (...
Saved in:
Published in | Gynecologic oncology Vol. 59; no. 1; pp. 38 - 44 |
---|---|
Main Authors | , , , |
Format | Journal Article Conference Proceeding |
Language | English |
Published |
San Diego, CA
Elsevier Inc
01.10.1995
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Between 1960 and 1989 1538 patients were treated with initial radiation therapy for FIGO Stage IB squamous cell carcinoma (SCC) of the cervix and 229 patients were treated for Stage IB adenocarcinoma (AC). The overall 5-year survival rates for patients with SCC and AC were 81 and 72%, respectively (
P < 0.01). Patients with AC more often had a maximum cervical diameter <4 cm than those with SCC (53% versus 47%). For 903 patients with tumors ⩾4 cm, 73% of those with SCC survived ⩾5 years compared with only 59% of those with AC (
P < 0.01). Although there was no significant difference in the rate of pelvic disease recurrence for patients with AC or SCC tumors ⩾4 cm (17% versus 13%,
P = 0.16), the rate of distant metastases was greater for patients with AC (37% vs 21%,
P < 0.01). For patients with tumors ⩾4 cm, prognosis was strongly correlated with tumor size (
P < 0.01) and lymphangiogram findings (
P < 0.01) but not with age (
P = 0.58) or tumor morphology (exophytic versus endocervical) (
P = 0.33); a trend toward better survival in 165 patients wire underwent adjuvant hysterectomy (78% versus 71%) was not significant (
P = 11.09). Multivariate analysis confirmed a highly significant independent association between histology and survival; patients with tumors ⩾4 cm in diameter that were AC had an estimated risk of death 1.9 times that of patients with SCC (
P < 0.01). These results provide strong evidence that patients with AC of the cervix have a poorer prognosis than those with SCC of similar stage and tumor diameter, reflecting primarily a higher rate of distant metastases in patients with AC. |
---|---|
AbstractList | Between 1960 and 1989 1538 patients were treated with initial radiation therapy for FIGO Stage IB squamous cell carcinoma (SCC) of the cervix and 229 patients were treated for Stage IB adenocarcinoma (AC). The overall 5-year survival rates for patients with SCC and AC were 81 and 72%, respectively (P < 0.01). Patients with AC more often had a maximum cervical diameter < 4 cm than those with SCC (53% versus 47%). For 903 patients with tumors > or = 4 cm, 73% of those with SCC survived > or = 5 years compared with only 59% of those with AC (P < 0.01). Although there was no significant difference in the rate of pelvic disease recurrence for patients with AC or SCC tumors > or = 4 cm (17% versus 13%, P = 0.16), the rate of distant metastases was greater for patients with AC (37% vs 21%, P < 0.01). For patients with tumors > or = 4 cm, prognosis was strongly correlated with tumor size (P < 0.01) and lymphangiogram findings (P < 0.01) but not with age (P = 0.58) or tumor morphology (exophytic versus endocervical) (P = 0.33); a trend toward better survival in 165 patients who underwent adjuvant hysterectomy (78% versus 71%) was not significant (P = 0.09). Multivariate analysis confirmed a highly significant independent association between histology and survival; patients with tumors > or = 4 cm in diameter that were AC had an estimated risk of death 1.9 times that of patients with SCC (P < 0.01). These results provide strong evidence that patients with AC of the cervix have a poorer prognosis than those with SCC of similar stage and tumor diameter, reflecting primarily a higher rate of distant metastases in patients with AC. Between 1960 and 1989 1538 patients were treated with initial radiation therapy for FIGO Stage IB squamous cell carcinoma (SCC) of the cervix and 229 patients were treated for Stage IB adenocarcinoma (AC). The overall 5-year survival rates for patients with SCC and AC were 81 and 72%, respectively (P < 0.01). Patients with AC more often had a maximum cervical diameter < 4 cm than those with SCC (53% versus 47%). For 903 patients with tumors > or = 4 cm, 73% of those with SCC survived > or = 5 years compared with only 59% of those with AC (P < 0.01). Although there was no significant difference in the rate of pelvic disease recurrence for patients with AC or SCC tumors > or = 4 cm (17% versus 13%, P = 0.16), the rate of distant metastases was greater for patients with AC (37% vs 21%, P < 0.01). For patients with tumors > or = 4 cm, prognosis was strongly correlated with tumor size (P < 0.01) and lymphangiogram findings (P < 0.01) but not with age (P = 0.58) or tumor morphology (exophytic versus endocervical) (P = 0.33); a trend toward better survival in 165 patients who underwent adjuvant hysterectomy (78% versus 71%) was not significant (P = 0.09). Multivariate analysis confirmed a highly significant independent association between histology and survival; patients with tumors > or = 4 cm in diameter that were AC had an estimated risk of death 1.9 times that of patients with SCC (P < 0.01). These results provide strong evidence that patients with AC of the cervix have a poorer prognosis than those with SCC of similar stage and tumor diameter, reflecting primarily a higher rate of distant metastases in patients with AC. Between 1960 and 1989 1538 patients were treated with initial radiation therapy for FIGO Stage IB squamous cell carcinoma (SCC) of the cervix and 229 patients were treated for Stage IB adenocarcinoma (AC). The overall 5-year survival rates for patients with SCC and AC were 81 and 72%, respectively ( P < 0.01). Patients with AC more often had a maximum cervical diameter <4 cm than those with SCC (53% versus 47%). For 903 patients with tumors ⩾4 cm, 73% of those with SCC survived ⩾5 years compared with only 59% of those with AC ( P < 0.01). Although there was no significant difference in the rate of pelvic disease recurrence for patients with AC or SCC tumors ⩾4 cm (17% versus 13%, P = 0.16), the rate of distant metastases was greater for patients with AC (37% vs 21%, P < 0.01). For patients with tumors ⩾4 cm, prognosis was strongly correlated with tumor size ( P < 0.01) and lymphangiogram findings ( P < 0.01) but not with age ( P = 0.58) or tumor morphology (exophytic versus endocervical) ( P = 0.33); a trend toward better survival in 165 patients wire underwent adjuvant hysterectomy (78% versus 71%) was not significant ( P = 11.09). Multivariate analysis confirmed a highly significant independent association between histology and survival; patients with tumors ⩾4 cm in diameter that were AC had an estimated risk of death 1.9 times that of patients with SCC ( P < 0.01). These results provide strong evidence that patients with AC of the cervix have a poorer prognosis than those with SCC of similar stage and tumor diameter, reflecting primarily a higher rate of distant metastases in patients with AC. |
Author | Eifel, P.J. Morris, M. Burke, T.W. Smith, T.L. |
Author_xml | – sequence: 1 givenname: P.J. surname: Eifel fullname: Eifel, P.J. – sequence: 2 givenname: T.W. surname: Burke fullname: Burke, T.W. – sequence: 3 givenname: M. surname: Morris fullname: Morris, M. – sequence: 4 givenname: T.L. surname: Smith fullname: Smith, T.L. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3697185$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/7557613$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kEtPWzEQRi1EBYF2y66SF1V3N9hx_FrSlEckpFa0XVsTe0JNEzu1b0D8e3yVwI6F7cUcfzNzTshhygkJOeNszBlT5_fPKY-5tXLMJ0oekBFnVnbKSHtIRoxZ1pmJNMfkpNYHxphgfHJEjrSUWnExIpuLgCl7KD6mvAYKlUKi8xRwg-1KPb2L9R-9At_nQpftfI8VoSK9Q78tBZNHGhP9CX1sdKVPsf9Lf_Vwj3T-jc6wPEYPKzp77fCRfFjCquKn_XtK_lxd_p7ddLc_ruezi9vOC2X6bmomEIwJxkqjPTcKBC5QGAYcNUirlfIMFlwIzlEy681CBwhT7dtmjE_FKfm6y92U_H-LtXfrWD2uVpAwb6vTTUEzwBs43oG-5FoLLt2mxDWUZ8eZGxS7QbEbFLtBcfvweZ-8XawxvOF7p63-ZV-H2lZfFkg-1jdMKKu5GWLMDsNm4TFicdXHQWeIBX3vQo7vTfACdaqZKQ |
CODEN | GYNOA3 |
CitedBy_id | crossref_primary_10_1046_j_1525_1438_2000_010004305_x crossref_primary_10_1097_IGC_0000000000001009 crossref_primary_10_1016_j_gofs_2019_02_006 crossref_primary_10_1177_0300060518803041 crossref_primary_10_1007_s00066_012_0123_2 crossref_primary_10_1111_j_1525_1438_2005_00164_x crossref_primary_10_1097_IGC_0000000000001088 crossref_primary_10_1016_S1297_9589_02_00318_1 crossref_primary_10_1111_jog_13282 crossref_primary_10_1111_j_1349_7006_2010_01812_x crossref_primary_10_1016_j_radonc_2014_03_025 crossref_primary_10_17116_onkolog20176176_80 crossref_primary_10_1186_s12885_022_10277_0 crossref_primary_10_1007_s10147_008_0861_4 crossref_primary_10_1016_j_ygyno_2013_01_007 crossref_primary_10_1002_cncr_11679 crossref_primary_10_1016_j_jfma_2012_10_021 crossref_primary_10_1002_1097_0142_20011101_92_9_2471__AID_CNCR1597_3_0_CO_2_K crossref_primary_10_1038_s41598_020_73523_0 crossref_primary_10_1016_j_ijrobp_2010_07_011 crossref_primary_10_1111_j_1525_1438_2008_01195_x crossref_primary_10_1002_ijc_22678 crossref_primary_10_1016_j_ijrobp_2004_04_030 crossref_primary_10_1016_j_asjsur_2021_06_063 crossref_primary_10_1006_gyno_1998_5046 crossref_primary_10_1200_JCO_2017_77_3416 crossref_primary_10_1016_S0360_3016_98_00255_7 crossref_primary_10_1158_1078_0432_CCR_09_0560 crossref_primary_10_1016_j_ygyno_2013_04_470 crossref_primary_10_1002_14651858_CD006248_pub3 crossref_primary_10_1016_S0002_9378_98_70313_8 crossref_primary_10_1097_IGC_0000000000000263 crossref_primary_10_1038_sj_bjc_6605705 crossref_primary_10_1046_j_1525_1438_2002_01089_x crossref_primary_10_1186_s12920_022_01376_9 crossref_primary_10_1007_s12253_015_9906_y crossref_primary_10_1016_j_ygyno_2021_08_004 crossref_primary_10_1016_S0959_8049_02_00315_5 crossref_primary_10_1016_S0889_8545_02_00023_2 crossref_primary_10_1016_j_semradonc_2011_12_009 crossref_primary_10_1006_gyno_2000_5935 crossref_primary_10_1006_gyno_2001_6473 crossref_primary_10_1006_gyno_1998_5291 crossref_primary_10_1016_j_ejogrb_2006_10_021 crossref_primary_10_1016_j_ejso_2005_01_003 crossref_primary_10_1016_j_ijsu_2017_03_024 crossref_primary_10_1016_j_plefa_2008_10_003 crossref_primary_10_18632_aging_205397 crossref_primary_10_1016_j_omto_2020_09_001 crossref_primary_10_1002_cncr_11371 crossref_primary_10_1007_s11864_015_0386_9 crossref_primary_10_1159_000511564 crossref_primary_10_1006_gyno_1999_5434 crossref_primary_10_1093_jjco_hyz200 crossref_primary_10_1097_IGC_0000000000000650 crossref_primary_10_1002_ijc_30636 crossref_primary_10_1016_j_ygyno_2014_08_014 crossref_primary_10_1016_j_ygyno_2007_07_080 crossref_primary_10_3390_medicina56040152 crossref_primary_10_3802_jgo_2013_24_3_222 crossref_primary_10_1093_ajcp_aqx077 crossref_primary_10_5402_2012_817065 crossref_primary_10_1002_jso_21499 crossref_primary_10_1016_j_path_2010_12_006 crossref_primary_10_1007_s00261_016_0825_5 crossref_primary_10_1016_j_ygyno_2006_01_009 crossref_primary_10_1186_s12905_022_01971_z crossref_primary_10_1038_sj_bjc_6605048 crossref_primary_10_1016_j_ejogrb_2011_12_029 crossref_primary_10_1586_eog_11_74 crossref_primary_10_3802_jgo_2017_28_e81 crossref_primary_10_1016_j_gyobfe_2003_10_028 crossref_primary_10_1016_j_ijsu_2017_05_074 crossref_primary_10_1097_IGC_0000000000000763 crossref_primary_10_1159_000369387 crossref_primary_10_1046_j_1525_1438_1999_09895_x crossref_primary_10_1002_cam4_971 crossref_primary_10_2165_00024669_200302040_00004 crossref_primary_10_1007_s10147_017_1225_8 crossref_primary_10_1016_j_jfma_2022_10_012 crossref_primary_10_1016_j_vaccine_2011_09_115 crossref_primary_10_3802_jgo_2022_33_e82 crossref_primary_10_3892_mco_2013_112 crossref_primary_10_1016_j_ejogrb_2019_01_028 crossref_primary_10_1620_tjem_254_145 crossref_primary_10_1002_1097_0142_20011215_92_12_2999__AID_CNCR10145_3_0_CO_2_1 crossref_primary_10_16919_bozoktip_467455 crossref_primary_10_1016_j_ijrobp_2010_02_009 crossref_primary_10_1007_s11033_013_2969_5 crossref_primary_10_1158_1078_0432_CCR_07_4085 crossref_primary_10_1007_s00259_009_1336_1 crossref_primary_10_1002_ijc_21813 crossref_primary_10_1016_S0360_3016_02_04525_X crossref_primary_10_1111_j_1048_891X_2004_014504_x crossref_primary_10_1016_j_clon_2008_03_001 crossref_primary_10_1016_j_ygyno_2003_08_020 crossref_primary_10_1016_j_ygyno_2015_05_016 crossref_primary_10_1111_j_1525_1438_2006_00628_x crossref_primary_10_1038_bjc_2013_716 crossref_primary_10_1016_j_brachy_2022_06_009 crossref_primary_10_1002_cncr_24822 crossref_primary_10_1097_IGC_0000000000000197 crossref_primary_10_1080_01443615_2016_1245279 crossref_primary_10_1016_j_ygyno_2015_06_035 crossref_primary_10_3802_jgo_2017_28_e34 crossref_primary_10_1111_j_1048_891X_2004_014211_x crossref_primary_10_1016_j_ygyno_2014_01_048 crossref_primary_10_1016_j_ygyno_2011_06_024 crossref_primary_10_1093_jjco_hyq053 crossref_primary_10_1016_j_ijrobp_2011_12_013 crossref_primary_10_1016_j_ygyno_2012_06_024 crossref_primary_10_15406_jcpcr_2015_02_00058 crossref_primary_10_1007_s10147_016_1010_0 crossref_primary_10_1097_PGP_0000000000000612 crossref_primary_10_1002_cncr_28916 crossref_primary_10_1046_j_1525_1438_1998_09796_x crossref_primary_10_1054_cuog_2000_0108 crossref_primary_10_1245_s10434_008_0185_7 crossref_primary_10_1186_s12885_018_5007_0 crossref_primary_10_7314_APJCP_2014_15_6_2815 crossref_primary_10_1007_s11912_015_0440_6 crossref_primary_10_3892_ol_2015_3105 crossref_primary_10_1016_j_ijgo_2011_06_011 crossref_primary_10_1046_j_1525_1438_1999_09873_x crossref_primary_10_1016_j_ygyno_2014_10_004 crossref_primary_10_1097_MD_0000000000009323 crossref_primary_10_1016_j_ajog_2011_07_029 crossref_primary_10_1245_s10434_012_2768_6 crossref_primary_10_3802_jgo_2011_22_1_32 crossref_primary_10_1371_journal_pone_0122557 crossref_primary_10_1097_IGC_0000000000000063 crossref_primary_10_1186_s12893_023_02203_3 crossref_primary_10_1016_j_ejro_2022_100433 crossref_primary_10_1016_S0046_8177_98_90117_4 crossref_primary_10_1016_j_ygyno_2012_01_034 crossref_primary_10_1007_s00404_010_1511_4 crossref_primary_10_1007_s11912_014_0416_y crossref_primary_10_1186_1471_2407_13_553 crossref_primary_10_1093_jrr_rrt086 crossref_primary_10_4236_ojog_2014_414128 crossref_primary_10_1155_2020_3981529 crossref_primary_10_1006_gyno_1998_5093 crossref_primary_10_1136_ijgc_2019_000647 crossref_primary_10_1590_1806_93042019000300009 crossref_primary_10_1016_j_ijgo_2010_08_016 crossref_primary_10_3892_mco_2014_295 crossref_primary_10_18632_oncotarget_17574 crossref_primary_10_1371_journal_pone_0139748 crossref_primary_10_1186_1471_2407_7_164 crossref_primary_10_1016_S0895_6111_97_00007_4 crossref_primary_10_1007_s00280_017_3402_x crossref_primary_10_1016_j_critrevonc_2019_01_006 crossref_primary_10_5301_tj_5000697 crossref_primary_10_1002_cncr_24400 crossref_primary_10_3892_ol_2015_3015 crossref_primary_10_1016_j_ygyno_2007_02_019 crossref_primary_10_1016_j_ygyno_2009_09_040 crossref_primary_10_1006_gyno_1997_4886 crossref_primary_10_1111_IGC_0b013e3181a12ea6 crossref_primary_10_1016_j_neo_2018_08_010 crossref_primary_10_18632_oncotarget_12598 crossref_primary_10_1158_1055_9965_EPI_08_0965 crossref_primary_10_3390_ijms21114117 crossref_primary_10_1002_jcb_28007 crossref_primary_10_1016_j_ejogrb_2020_06_030 crossref_primary_10_1016_j_ygyno_2007_01_045 crossref_primary_10_5794_jjoms_59_617 crossref_primary_10_1006_gyno_1998_4971 crossref_primary_10_1016_j_ygyno_2012_03_008 crossref_primary_10_1016_j_jgyn_2012_07_003 crossref_primary_10_1016_j_ejso_2024_107977 crossref_primary_10_1016_j_ajog_2007_08_055 crossref_primary_10_1067_mob_2002_127906 crossref_primary_10_1006_gyno_1999_5364 crossref_primary_10_1016_j_ygyno_2010_11_022 crossref_primary_10_1002_cncr_28288 crossref_primary_10_1002_cncr_28722 crossref_primary_10_1002_ijc_34242 crossref_primary_10_1016_j_ajog_2005_06_029 crossref_primary_10_1016_j_ogc_2012_02_008 crossref_primary_10_1007_s00262_015_1678_4 crossref_primary_10_1007_s40944_022_00677_2 crossref_primary_10_1097_00006250_199902000_00012 crossref_primary_10_3390_cancers14163934 crossref_primary_10_1097_IGC_0b013e3182a3402f |
ContentType | Journal Article Conference Proceeding |
Copyright | 1995 Academic Press 1995 INIST-CNRS |
Copyright_xml | – notice: 1995 Academic Press – notice: 1995 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1006/gyno.1995.1265 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1095-6859 |
EndPage | 44 |
ExternalDocumentID | 10_1006_gyno_1995_1265 7557613 3697185 S0090825885712656 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29I 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAXUO ABBQC ABFNM ABFRF ABJNI ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LCYCR LG5 M29 M41 MO0 N9A O-L O9- OAUVE OQ. OZT P-8 P-9 P2P PC. PH~ Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SES SEW SPCBC SSH SSZ T5K UDS UHS UV1 WUQ X7M XPP Z5R ZGI ZMT ZU3 ZXP ~G- 08R AAPBV AAUGY ABPIF ABPTK IQODW AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c368t-482ad88d89587c186a3ebe380a1e7a59766c0ab13311e509c8b7dad47c5570143 |
IEDL.DBID | AIKHN |
ISSN | 0090-8258 |
IngestDate | Fri Oct 25 23:00:39 EDT 2024 Thu Sep 26 18:59:08 EDT 2024 Sat Sep 28 07:34:29 EDT 2024 Sun Oct 22 16:08:28 EDT 2023 Fri Feb 23 02:25:58 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Adenocarcinoma Human Relapse Carcinoma Prognosis Early stage Histology Malignant tumor Uterine cervix Statistical study Female genital diseases Follow up study Risk factor Female Uterine cervix diseases |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c368t-482ad88d89587c186a3ebe380a1e7a59766c0ab13311e509c8b7dad47c5570143 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 7557613 |
PQID | 77556131 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_77556131 crossref_primary_10_1006_gyno_1995_1265 pubmed_primary_7557613 pascalfrancis_primary_3697185 elsevier_sciencedirect_doi_10_1006_gyno_1995_1265 |
PublicationCentury | 1900 |
PublicationDate | 1995-10-01 |
PublicationDateYYYYMMDD | 1995-10-01 |
PublicationDate_xml | – month: 10 year: 1995 text: 1995-10-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | San Diego, CA |
PublicationPlace_xml | – name: San Diego, CA – name: United States |
PublicationTitle | Gynecologic oncology |
PublicationTitleAlternate | Gynecol Oncol |
PublicationYear | 1995 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
SSID | ssj0003012 |
Score | 1.9750477 |
Snippet | Between 1960 and 1989 1538 patients were treated with initial radiation therapy for FIGO Stage IB squamous cell carcinoma (SCC) of the cervix and 229 patients... |
SourceID | proquest crossref pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 38 |
SubjectTerms | Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - radiotherapy Adult Biological and medical sciences Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - radiotherapy Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Medical sciences Middle Aged Neoplasm Recurrence, Local - epidemiology Neoplasm Staging Risk Factors Survival Rate Treatment Outcome Tumors Uterine Cervical Neoplasms - mortality Uterine Cervical Neoplasms - pathology Uterine Cervical Neoplasms - radiotherapy |
Title | Adenocarcinoma as an Independent Risk Factor for Disease Recurrence in Patients with Stage IB Cervical Carcinoma |
URI | https://dx.doi.org/10.1006/gyno.1995.1265 https://www.ncbi.nlm.nih.gov/pubmed/7557613 https://search.proquest.com/docview/77556131 |
Volume | 59 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT9swFH6CIiGkCbENNDYKPkzaKTR2Ets5lkLVrgJN1RDcLNtxUYWWVqQ9cOFv33OcVOLQC6cosZw8vc957_OP9x7ATxnnTBTWRq6YmSiV6Swy8cxFzOWWJWlsc-2jkW_v-Og-_f2YPe7AoI2F8ccqG9sfbHptrZsnvUabveV87mN8fbnuTMpMUIa0ZBf20B0x2YG9_ngyutsYZBzDIWl4HTWdyTZ3Y8x7T6_lwgfsZZf-Fdt806elrlBjs1DqYjsXrX3S8AgOGzJJ-kHez7Djyi-wf9tsl3-FZR-tCjqrF7xd_NNEV0SXZLypfLsi03n1TIZ1zR2C9JVch_0aMvXL8HUgIJmX5E9IvloRv2pLkJ8-OTK-IoPazqAAg_YLx3A_vPk7GEVNiYXIJlyuEBymCykLmWdSWCq5ThDVRMaaOqFxssG5jbXBiSylDrmFlUYUukiF9am7kGudQKdclO4bEK4ZNQk1udEpcrTExNpSExcF00izGD2FX61y1TJk0lAhZzJXHgblYVAehlOgre7Vu7Gg0Mxv7dN9B9LmEwnP0f1i-0ULmsIfyO-K6NIt1pUSwlcITVC-k4Dlpis2CGz5_gFxfsBBHften_o7g87qZe26yF5W5hx2L9_oeTNG_XUyfZj8B9378GA |
link.rule.ids | 310,311,315,783,787,792,793,4509,23942,23943,24128,25152,27936,27937,45597,45691 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELZ4SICEEE9RXvWAxBQa52E7IxSqFlqEEEhslu24qEKkVVMGFn47ZzspYujCmFhOTvdd7r7YvjuEznmYRSzXOjD5UAUJT4aBCocmiEymozgJdSZtNvLggXZfkrvX9HUJtetcGHussvL93qc7b13daVXabE1GI5vja9t1p5ynjERAS5bRamL5MRj15ffvOQ-wYF8y3OVMp7yu3BjS1ttXMbbpeumlfcCiyLQ5kSXoa-gbXSxmoi4idbbRVkUl8ZWXdgctmWIXrQ2qzfI9NLkCnwKhagqX4w-JZYllgXvzvrcz_DQq33HHddzBQF7xjd-twU92Ed6lAeJRgR996dUS2zVbDOz0zeDeNW47LwMCtOs37KOXzu1zuxtUDRYCHVM-A2gimXOe8yzlTBNOZQyYxjyUxDAJqqRUh1LBbywhBpiF5orlMk-YtoW7gGkdoJViXJhDhKmMiIqJypRMgKHFKpSaqDDPIwkkKyINdFErV0x8HQ3hKyZTYWEQFgZhYWggUute_LEEAU5-4ZzTPyDNXxHTDIIvjDdr0AR8PnZPRBZm_FkKxmx_0BjkO_BYzqfCAIORo3-I00Tr3edBX_R7D_fHaMNlwbvzfydoZTb9NKfAY2bqzNnpD4om75Y |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=proceeding&rft.title=Gynecologic+oncology+%28Print%29&rft.atitle=Adenocarcinoma+as+an+independent+risk+factor+for+disease+recurrence+in+patients+with+stage+IB+cervical+carcinoma&rft.au=EIFEL%2C+P.+J&rft.au=BURKE%2C+T.+W&rft.au=MORRIS%2C+M&rft.au=SMITH%2C+T.+L&rft.date=1995-10-01&rft.pub=Elsevier&rft.issn=0090-8258&rft.eissn=1095-6859&rft.volume=59&rft.issue=1&rft.spage=38&rft.epage=44&rft_id=info:doi/10.1006%2Fgyno.1995.1265&rft.externalDBID=n%2Fa&rft.externalDocID=3697185 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-8258&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-8258&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-8258&client=summon |